110 related articles for article (PubMed ID: 7015139)
41. A Short History of Bernard Fisher's Contributions to Randomized Clinical Trials.
Anderson S
Clin Trials; 2022 Apr; 19(2):127-136. PubMed ID: 34991349
[TBL] [Abstract][Full Text] [Related]
42. A careful reassessment of anthracycline use in curable breast cancer.
Hurvitz SA; McAndrew NP; Bardia A; Press MF; Pegram M; Crown JP; Fasching PA; Ejlertsen B; Yang EH; Glaspy JA; Slamon DJ
NPJ Breast Cancer; 2021 Oct; 7(1):134. PubMed ID: 34625570
[TBL] [Abstract][Full Text] [Related]
43. Serine synthesis influences tamoxifen response in ER+ human breast carcinoma.
Metcalf S; Petri BJ; Kruer T; Green B; Dougherty S; Wittliff JL; Klinge CM; Clem BF
Endocr Relat Cancer; 2021 Jan; 28(1):27-37. PubMed ID: 33112838
[TBL] [Abstract][Full Text] [Related]
44. Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas.
Sereff SB; Daniels MW; Wittliff JL
J Clin Lab Anal; 2019 Nov; 33(9):e22982. PubMed ID: 31359505
[TBL] [Abstract][Full Text] [Related]
45. A Novel Tomato-Soy Juice Induces a Dose-Response Increase in Urinary and Plasma Phytochemical Biomarkers in Men with Prostate Cancer.
Grainger EM; Moran NE; Francis DM; Schwartz SJ; Wan L; Thomas-Ahner J; Kopec RE; Riedl KM; Young GS; Abaza R; Bahnson RR; Clinton SK
J Nutr; 2019 Jan; 149(1):26-35. PubMed ID: 30476157
[TBL] [Abstract][Full Text] [Related]
46. Expression of Genes for Methylxanthine Pathway-Associated Enzymes Accompanied by Sex Steroid Receptor Status Impacts Breast Carcinoma Progression.
Wittliff JL; Sereff SB; Daniels MW
Horm Cancer; 2017 Dec; 8(5-6):298-313. PubMed ID: 28971320
[TBL] [Abstract][Full Text] [Related]
47. Milestone clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP).
Rastogi P; Wickerham DL; Geyer CE; Mamounas EP; Julian TB; Wolmark N
Chin Clin Oncol; 2017 Feb; 6(1):7. PubMed ID: 28285537
[TBL] [Abstract][Full Text] [Related]
48. Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives.
Myers MB
Pharmgenomics Pers Med; 2016; 9():7-16. PubMed ID: 26858530
[TBL] [Abstract][Full Text] [Related]
49. Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies.
Hicks D; Dell'Orto P; Falzon M; Hoff KD; Levy YY; McMahon L; Miller K; Russo L; Viale G
Appl Immunohistochem Mol Morphol; 2017; 25(5):313-319. PubMed ID: 26657878
[TBL] [Abstract][Full Text] [Related]
50. Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments.
Stover DG; Wagle N
Curr Oncol Rep; 2015 Apr; 17(4):15. PubMed ID: 25708799
[TBL] [Abstract][Full Text] [Related]
51. A Brief History of Breast Cancer: Part III - Tumour biology lays the foundation for medical oncology.
Lakhtakia R; Burney I
Sultan Qaboos Univ Med J; 2015 Feb; 15(1):e34-8. PubMed ID: 25685382
[No Abstract] [Full Text] [Related]
52. Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.
Schink JC; Trosman JR; Weldon CB; Siziopikou KP; Tsongalis GJ; Rademaker AW; Patel JD; Benson AB; Perez EA; Gradishar WJ
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25217578
[TBL] [Abstract][Full Text] [Related]
53. Predicting targeted drug combinations based on Pareto optimal patterns of coexpression network connectivity.
Penrod NM; Greene CS; Moore JH
Genome Med; 2014; 6(4):33. PubMed ID: 24944582
[TBL] [Abstract][Full Text] [Related]
54. In situ Protein Detection for Companion Diagnostics.
Gremel G; Grannas K; Sutton LA; Pontén F; Zieba A
Front Oncol; 2013 Oct; 3():271. PubMed ID: 24199171
[TBL] [Abstract][Full Text] [Related]
55. The G-protein coupled estrogen receptor (GPER/GPR30) is a gonadotropin receptor dependent positive prognosticator in ovarian carcinoma patients.
Heublein S; Mayr D; Vrekoussis T; Friese K; Hofmann SS; Jeschke U; Lenhard M
PLoS One; 2013; 8(8):e71791. PubMed ID: 23951246
[TBL] [Abstract][Full Text] [Related]
56. Protein tyrosine phosphatase 4A2 expression predicts overall and disease-free survival of human breast cancer and is associated with estrogen and progestin receptor status.
Andres SA; Wittliff JL; Cheng A
Horm Cancer; 2013 Aug; 4(4):208-21. PubMed ID: 23568563
[TBL] [Abstract][Full Text] [Related]
57. Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas.
Sorbye SW; Kilvaer TK; Valkov A; Donnem T; Smeland E; Al-Shibli K; Bremnes RM; Busund LT
BMC Clin Pathol; 2013 Mar; 13():9. PubMed ID: 23497154
[TBL] [Abstract][Full Text] [Related]
58. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.
Gonzalez-Angulo AM; Blumenschein GR
Cancer Treat Rev; 2013 Jun; 39(4):313-20. PubMed ID: 23218708
[TBL] [Abstract][Full Text] [Related]
59. Two hundred years of cancer research.
DeVita VT; Rosenberg SA
N Engl J Med; 2012 Jun; 366(23):2207-14. PubMed ID: 22646510
[No Abstract] [Full Text] [Related]
60. Cytoplasmic estrogen receptor in breast cancer.
Welsh AW; Lannin DR; Young GS; Sherman ME; Figueroa JD; Henry NL; Ryden L; Kim C; Love RR; Schiff R; Rimm DL
Clin Cancer Res; 2012 Jan; 18(1):118-26. PubMed ID: 21980134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
